Hydroxyacid dehydrogenases limit the conversion of α-keto acids into aroma compounds. Here we report that inactivation of the panE gene, encoding the α-hydroxyacid dehydrogenase activity in Lactococcus lactis, enhanced the formation of 3-methylbutanal and 3-methylbutanol. L. lactis IFPL953ΔpanE was an efficient strain producing volatile compounds related to cheese aroma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648031 | PMC |
| http://dx.doi.org/10.1128/AEM.00279-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
J Neurol
September 2024
Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University, Naples, Italy.
Introduction: Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting.
Methods: We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG).
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Mol Oncol
April 2024
Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas with a poor survival rate, presenting either sporadically or in the context of neurofibromatosis type 1 (NF1). The histological diagnosis of MPNSTs can be challenging, with different tumors exhibiting great histological and marker expression overlap. This heterogeneity could be partly responsible for the observed disparity in treatment response due to the inherent diversity of the preclinical models used.
View Article and Find Full Text PDFEfficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Eur J Neurol
December 2023
Department of Health Sciences, University of Genoa, Genoa, Italy.
Article Synopsis
- New therapies for myasthenia gravis (MG), such as complement inhibitors and FcRn blockers, are being analyzed for their effectiveness through meta-analysis of randomized trials.
- The study found that both anti-complement and FcRn treatments resulted in significant improvements in MG symptoms, with efgartigimod showing the highest likelihood of being the best treatment option.
- In contrast, rituximab did not demonstrate a significant benefit for MG patients, highlighting the need for further long-term studies to validate these findings.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Eur J Haematol
September 2022
Hôpital Saint-Louis AP-HP, Paris, France.
Article Synopsis
- - The study evaluated the long-term effects of ravulizumab, a C5 inhibitor, on patients with paroxysmal nocturnal hemoglobinuria (PNH) over a period from 27 weeks to 2 years after initial treatment.
- - Results showed sustained improvements in key health indicators such as lactate dehydrogenase (LDH) levels and a significant rate of transfusion avoidance, with 81.9% to 85.6% of patients avoiding transfusions.
- - Overall, ravulizumab was well tolerated during this extended period, with a low incidence of serious adverse events, confirming its effectiveness and safety as a primary treatment option for PNH.
Antimicrobial Effects of Chemically Functionalized and/or Photo-Heated Nanoparticles.
Materials (Basel)
April 2019
CNR-Lab. Licryl, Institute NANOTEC, 87036 Arcavacata di Rende, Italy.
Antibiotic resistance refers to when microorganisms survive and grow in the presence of specific antibiotics, a phenomenon mainly related to the indiscriminate widespread use and abuse of antibiotics. In this framework, thanks to the design and fabrication of original functional nanomaterials, nanotechnology offers a powerful weapon against several diseases such as cancer and pathogenic illness. Smart nanomaterials, such as metallic nanoparticles and semiconductor nanocrystals, enable the realization of novel drug-free medical therapies for fighting against antibiotic-resistant bacteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!